AMD 

Cataract & Refractive

Cornea

Gene Therapy

Glaucoma

Inflammation & Infection

Paediatrics

Retina

Articles

Media

All Videos

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Publications

Digital Edition

Supplements And Featured Publications

Conferences

Conference Listing 

CME/CE

Resources

ZEISS Clinical Cases

Zeiss Cataract Insights

Zeiss Cataract Digitalization

Enhancing the Patient Journey

EYLEA 8mg for nAMD and DME Treatment

Between the Lines

Subscribe

Advertise

About Us

Editorial Info

Editorial Board

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Ophthalmology Times Europe

Facebook

LinkedIn

Spotlight

High-Frequency Deep Sclerotomy

iCare COMPASS Automated Perimeter

Clinical

Video Series

1rem

EYLEA 8mg for the treatment of neovascular age-related macular degeneration and diabetic macular edema

Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11, and explore the practical implications of biosimilars in the broader real-world context.

Between the Lines: Expanding Treatment Options in Retina Diseases with Biosimilars

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

The state of wet & dry AMD in 2021